

# Francesco Angelico

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6879931/publications.pdf>

Version: 2024-02-01

84  
papers

3,483  
citations

136740

32  
h-index

149479

56  
g-index

85  
all docs

85  
docs citations

85  
times ranked

5407  
citing authors

#	ARTICLE	IF	CITATIONS
1	Statin liver safety in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 441-451.	1.1	28
2	Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 720.	1.4	5
3	Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review. <i>Nutrients</i> , 2022, 14, 1127.	1.7	22
4	High Compliance to Mediterranean Diet Associates with Lower Platelet Activation and Liver Collagen Deposition in Patients with Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 1209.	1.7	5
5	Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. <i>Annals of Medicine</i> , 2022, 54, 1548-1560.	1.5	39
6	Is the Mediterranean Diet the Best Approach to NAFLD Treatment Today?. <i>Nutrients</i> , 2021, 13, 739.	1.7	7
7	Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2683-2684.	2.4	6
8	Sex-Related Differences in the Association between Metabolic Syndrome and Gallstone Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1958.	1.2	3
9	Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?. <i>Digestive and Liver Disease</i> , 2021, 53, 383-384.	0.4	7
10	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 2063-2068.	1.0	5
11	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. <i>Pharmacological Research</i> , 2021, 165, 105418.	3.1	21
12	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8993.	1.2	10
13	The challenge of cardiovascular prevention in NAFLD. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 877-878.	3.7	5
14	Nonalcoholic Fatty Liver Disease and the Kidney: A Review. <i>Biomedicines</i> , 2021, 9, 1370.	1.4	6
15	Oxidative stress mediated platelet activation in patients with congenital analbuminemia: Effect of albumin infusion. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3090-3094.	1.9	4
16	Oleuropein-enriched chocolate by extra virgin olive oil blunts hyperglycaemia in diabetic patients: Results from a one-time 2-hour post-prandial cross over study. <i>Clinical Nutrition</i> , 2020, 39, 2187-2191.	2.3	13
17	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. <i>Digestive and Liver Disease</i> , 2020, 52, 359-367.	0.4	9
18	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events: A Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2324-2331.e4.	2.4	136

#	ARTICLE	IF	CITATIONS
19	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 513-520.	1.4	11
20	Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. <i>Hepatology</i> , 2020, 72, 470-485.	3.6	203
21	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. <i>Nutrients</i> , 2020, 12, 2762.	1.7	89
22	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Biomedicines</i> , 2020, 8, 625.	1.4	21
23	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 1732.	1.7	33
24	A systematic review on the association between obstructive sleep apnea and chronic kidney disease. <i>Sleep Medicine Reviews</i> , 2020, 53, 101337.	3.8	18
25	Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00116.	1.3	10
26	Association between non-alcoholic fatty liver disease and obstructive sleep apnea. <i>World Journal of Gastroenterology</i> , 2020, 26, 2669-2681.	1.4	32
27	Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil. <i>European Journal of Nutrition</i> , 2019, 58, 843-851.	1.8	25
28	Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 1325-1330.	2.5	20
29	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 2301-2308.	1.9	15
30	Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1087-1094.	1.1	19
31	Statins and non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1787-1787.	1.9	3
32	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2019, 25, 4172-4180.	1.4	23
33	Long-term prediction of adherence to continuous positive air pressure therapy for the treatment of moderate/severe obstructive sleep apnea syndrome. <i>Sleep Medicine</i> , 2018, 43, 66-70.	0.8	66
34	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. <i>Scientific Reports</i> , 2018, 8, 3702.	1.6	59
35	Role of NADPH oxidase-2 and oxidative stress in children exposed to passive smoking. <i>Thorax</i> , 2018, 73, 986-988.	2.7	16
36	Severity of OSAS, CPAP and cardiovascular events: A follow-up study. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12908.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Response to Duret et al.. American Journal of Gastroenterology, 2018, 113, 775-776.	0.2	0
38	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.4	48
39	Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2018, 7, 378.	1.0	36
40	Passive Smoking Exacerbates Nicotinamide-Adenine Dinucleotide Phosphate Oxidase Isoform 2 Induced Oxidative Stress and Arterial Dysfunction in Children with Persistent Allergic Rhinitis. Journal of Pediatrics, 2018, 202, 252-257.	0.9	9
41	Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. International Journal of Molecular Sciences, 2018, 19, 603.	1.8	7
42	Extra virgin olive oil improves post-prandial glycemic and lipid profile in patients with impaired fasting glucose. Clinical Nutrition, 2017, 36, 782-787.	2.3	50
43	The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. British Journal of Clinical Pharmacology, 2017, 83, 88-95.	1.1	74
44	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renal disease progression by aspirin in diabetic patients (LEDA) trial. Rationale and study design. American Heart Journal, 2017, 189, 120-127.	1.2	10
45	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis, 2017, 262, 179-184.	0.4	19
46	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically-versus genetically-driven excess fat hepatic storage. Atherosclerosis, 2017, 257, 232-239.	0.4	39
47	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. American Journal of Gastroenterology, 2017, 112, 1832-1839.	0.2	109
48	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. Internal and Emergency Medicine, 2017, 12, 1159-1165.	1.0	16
49	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. Scientific Reports, 2017, 7, 15756.	1.6	45
50	Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 161-167.	1.1	45
51	Chronic granulomatous disease as an SOS call for multicenter cooperative effort to prevent infections. Annals of Allergy, Asthma and Immunology, 2016, 117, 285-289.	0.5	7
52	Mediterranean diet and physical activity impact on metabolic syndrome among children and adolescents from Southern Italy: Contribution from the Calabrian Sierras Community Study (CSCS). International Journal of Cardiology, 2016, 225, 284-288.	0.8	19
53	Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with Type 2 diabetes. Clinical Science, 2016, 130, 1753-1762.	1.8	16
54	No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine, 2016, 14, 92.	2.3	130

#	ARTICLE	IF	CITATIONS
55	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. <i>Internal and Emergency Medicine</i> , 2016, 11, 199-204.	1.0	41
56	Does Lysosomal Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28014-28021.	1.8	18
57	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. <i>World Journal of Hepatology</i> , 2015, 7, 1325.	0.8	152
58	Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants. <i>Chest</i> , 2015, 147, 1644-1650.	0.4	59
59	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2015, 47, 4-11.	0.4	121
60	Relation of Nonalcoholic Fatty Liver Disease and Framingham Risk Score to Flow-Mediated Dilation in Patients With Cardiometabolic Risk Factors. <i>American Journal of Cardiology</i> , 2015, 115, 1402-1406.	0.7	24
61	Endothelial dysfunction and oxidative stress in children with sleep disordered breathing: Role of NADPH oxidase. <i>Atherosclerosis</i> , 2015, 240, 222-227.	0.4	49
62	Obstructive Sleep Apnea and the Metabolic Syndrome. , 2015, , 177-184.		0
63	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e113.	1.3	25
64	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. <i>EBioMedicine</i> , 2015, 2, 750-754.	2.7	51
65	Modern approach to the clinical management of non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 8341.	1.4	61
66	NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2014, 14, 81.	0.8	71
67	Strong interplay between metabolic syndrome, obstructive sleep apnoea, oxidative stress and arterial dysfunction. <i>Sleep and Breathing</i> , 2013, 18, 223-4.	0.9	2
68	Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 125-129.	0.4	1
69	Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. <i>Hepatology</i> , 2012, 56, 2180-2187.	3.6	192
70	Obesity and Hypercholesterolemia are Associated with NOX2 Generated Oxidative Stress and Arterial Dysfunction. <i>Journal of Pediatrics</i> , 2012, 161, 1004-1009.	0.9	74
71	Bleeding and thrombosis in cirrhotic patients: What really matters?. <i>Digestive and Liver Disease</i> , 2012, 44, 275-279.	0.4	34
72	Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. <i>Internal and Emergency Medicine</i> , 2012, 7, 291-296.	1.0	27

#	ARTICLE	IF	CITATIONS
73	Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment. <i>BMC Pulmonary Medicine</i> , 2012, 12, 36.	0.8	74
74	Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2012, 7, 219-227.	1.0	42
75	Moderate Weight Loss Decreases Oxidative Stress and Increases Antioxidant Status in Patients with Metabolic Syndrome. <i>ISRN Obesity</i> , 2012, 2012, 1-9.	2.2	12
76	Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. <i>BMC Medicine</i> , 2011, 9, 85.	2.3	257
77	Obstructive sleep apnoea syndrome and the metabolic syndrome in an internal medicine setting. <i>European Journal of Internal Medicine</i> , 2010, 21, 191-195.	1.0	43
78	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. , 2007, , CD005166.		61
79	Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. <i>The Cochrane Library</i> , 2007, , CD004996.	1.5	47
80	Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. <i>Free Radical Biology and Medicine</i> , 2007, 43, 853-859.	1.3	60
81	Gastric Cancer Precursor Lesions and Helicobacter pylori Infection in Patients with Partial Gastrectomy for Peptic Ulcer. <i>World Journal of Surgery</i> , 2005, 29, 1127-1130.	0.8	12
82	Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 588-594.	1.4	149
83	Attitudes and approach to cardiovascular risk factors in Italy: results of an electronic questionnaire survey. <i>Public Health</i> , 2003, 117, 242-249.	1.4	6
84	Recurrence of insulin resistant metabolic syndrome following liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 99-102.	0.8	14